Cargando…

Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions

Background: Eukaryotic elongation factor 2 kinase (eEF2K) regulates the elongation stage of protein synthesis by phosphorylating eEF2, a process related to various diseases including cancer and cardiovascular and neurodegenerative diseases. In this study, we describe the identification of novel eEF2...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimori, Atsushi, Kawasaki, Enzo, Murakami, Ryuta, Kanai, Chisato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161098/
https://www.ncbi.nlm.nih.gov/pubmed/34065377
http://dx.doi.org/10.3390/medicines8050023
_version_ 1783700433210966016
author Yoshimori, Atsushi
Kawasaki, Enzo
Murakami, Ryuta
Kanai, Chisato
author_facet Yoshimori, Atsushi
Kawasaki, Enzo
Murakami, Ryuta
Kanai, Chisato
author_sort Yoshimori, Atsushi
collection PubMed
description Background: Eukaryotic elongation factor 2 kinase (eEF2K) regulates the elongation stage of protein synthesis by phosphorylating eEF2, a process related to various diseases including cancer and cardiovascular and neurodegenerative diseases. In this study, we describe the identification of novel eEF2K inhibitors using high-throughput screening fingerprints (HTSFP) generated from predicted profiling of compound-protein interactions (CPIs). Methods: We utilized computationally generated HTSFPs referred to as chemical genomics-based fingerprint (CGBFP). Generally, HTSFPs are generated from multiple biochemical or cell-based assay data. On the other hand, CGBFPs are generated from computational prediction of CPIs using the Chemical Genomics-Based Virtual Screening (CGBVS) method. Therefore, CGBFPs do not have missing information mainly caused by the absence of assay data. Results: Chemogenomics-Based Similarity Profiling (CGBSP) of the screening library (2.6 million compounds) yielded 27 compounds which were evaluated for in vitro eEF2K inhibitory activity. Three compounds with interesting results were identified. Compounds 2 (IC [Formula: see text] = 11.05 μM) and 4 (IC [Formula: see text] = 43.54 μM) are thieno[2,3-b]pyridine derivatives that have the same scaffolds with a known eEF2K inhibitor, while compound 13 (IC [Formula: see text] = 70.13 μM) was a new thiophene-2-amine-type eEF2K inhibitor. Conclusions: CGBSP supplied an efficient strategy in the identification of novel eEF2K inhibitors and provided useful scaffolds for optimization.
format Online
Article
Text
id pubmed-8161098
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81610982021-05-29 Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions Yoshimori, Atsushi Kawasaki, Enzo Murakami, Ryuta Kanai, Chisato Medicines (Basel) Article Background: Eukaryotic elongation factor 2 kinase (eEF2K) regulates the elongation stage of protein synthesis by phosphorylating eEF2, a process related to various diseases including cancer and cardiovascular and neurodegenerative diseases. In this study, we describe the identification of novel eEF2K inhibitors using high-throughput screening fingerprints (HTSFP) generated from predicted profiling of compound-protein interactions (CPIs). Methods: We utilized computationally generated HTSFPs referred to as chemical genomics-based fingerprint (CGBFP). Generally, HTSFPs are generated from multiple biochemical or cell-based assay data. On the other hand, CGBFPs are generated from computational prediction of CPIs using the Chemical Genomics-Based Virtual Screening (CGBVS) method. Therefore, CGBFPs do not have missing information mainly caused by the absence of assay data. Results: Chemogenomics-Based Similarity Profiling (CGBSP) of the screening library (2.6 million compounds) yielded 27 compounds which were evaluated for in vitro eEF2K inhibitory activity. Three compounds with interesting results were identified. Compounds 2 (IC [Formula: see text] = 11.05 μM) and 4 (IC [Formula: see text] = 43.54 μM) are thieno[2,3-b]pyridine derivatives that have the same scaffolds with a known eEF2K inhibitor, while compound 13 (IC [Formula: see text] = 70.13 μM) was a new thiophene-2-amine-type eEF2K inhibitor. Conclusions: CGBSP supplied an efficient strategy in the identification of novel eEF2K inhibitors and provided useful scaffolds for optimization. MDPI 2021-05-20 /pmc/articles/PMC8161098/ /pubmed/34065377 http://dx.doi.org/10.3390/medicines8050023 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yoshimori, Atsushi
Kawasaki, Enzo
Murakami, Ryuta
Kanai, Chisato
Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions
title Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions
title_full Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions
title_fullStr Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions
title_full_unstemmed Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions
title_short Discovery of Novel eEF2K Inhibitors Using HTS Fingerprint Generated from Predicted Profiling of Compound-Protein Interactions
title_sort discovery of novel eef2k inhibitors using hts fingerprint generated from predicted profiling of compound-protein interactions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161098/
https://www.ncbi.nlm.nih.gov/pubmed/34065377
http://dx.doi.org/10.3390/medicines8050023
work_keys_str_mv AT yoshimoriatsushi discoveryofnoveleef2kinhibitorsusinghtsfingerprintgeneratedfrompredictedprofilingofcompoundproteininteractions
AT kawasakienzo discoveryofnoveleef2kinhibitorsusinghtsfingerprintgeneratedfrompredictedprofilingofcompoundproteininteractions
AT murakamiryuta discoveryofnoveleef2kinhibitorsusinghtsfingerprintgeneratedfrompredictedprofilingofcompoundproteininteractions
AT kanaichisato discoveryofnoveleef2kinhibitorsusinghtsfingerprintgeneratedfrompredictedprofilingofcompoundproteininteractions